INTRODUCTION {#Sec1}
============

With improving technology and accessibility, the use of clinical germline genetic testing for cancer risk assessment has increased significantly.^[@CR1],[@CR2]^ The most common modality of germline genetic testing for cancer risk assessment is multigene panel testing (MGPT), and the number of genes available for testing via MGPT continues to increase.^[@CR1],[@CR2]^ Pan-cancer and cancer site--specific MGPT is available for many cancer types including gastric cancer, which remains one of the most common cancers worldwide.^[@CR3]^ Based on the Lauren classification gastric cancer is classically divided between intestinal and diffuse types, with diffuse gastric cancer being the less common subtype seen in approximately 30% of cases.^[@CR4]^ While up to 20% of individuals diagnosed with gastric cancer have a family history of gastric cancer, only 1--3% of these cancers are thought to be due to a hereditary cancer risk syndrome caused by an identifiable genetic variant.^[@CR5]^ One of the best characterized syndromes is hereditary diffuse gastric cancer syndrome (HDGC), which is associated with an increased risk of diffuse gastric cancer as well as lobular breast cancer.^[@CR6]^ HDGC often results from germline pathogenic variants in the *CDH1* gene, which codes for the cell--cell adhesion protein E-cadherin. Germline testing for *CDH1* is recommended currently for individuals meeting HDGC testing criteria.^[@CR6]^

The majority of families meeting HDGC criteria do not have a detectable pathogenic *CDH1* variant. In 2013, exome sequencing identified a truncating variant in the *CTNNA1* gene in a HDGC family with no detectable germline *CDH1* variant.^[@CR7]^ *CTNNA1* codes for α-E-catenin, which is a protein that interacts with E-cadherin. Following this initial report, there have been subsequent publications documenting individuals with diffuse gastric cancer and truncating *CTNNA1* variants, highlighting the possibility that *CTNNA1* may be a gastric cancer risk gene similar to *CDH1*.^[@CR8]--[@CR11]^ However, unlike *CDH1*, the gastric cancer penetrance and whether *CTNNA1* is associated with increased breast cancer risk remain uncertain.

In addition to the unknown cancer penetrance, the appropriate management of individuals with loss-of-function (LOF) *CTNNA1* variants remains unclear. Carriers of pathogenic *CDH1* variants are typically recommended to undergo risk-reducing total gastrectomy, as gastric cancer screening in *CDH1* carriers is not effective.^[@CR12]^ While a recent report highlighted the first risk-reducing total gastrectomy performed in a *CTNNA1* carrier, there remain no clear guidelines about gastric cancer risk management in this group.^[@CR8]^ Much of the uncertainty related to the management of *CTNNA1* is due to the limited knowledge about the prevalence and penetrance of *CTNNA1* LOF variants, as until recently, commercial genetic testing laboratories did not offer clinical *CTNNA1* testing.

Herein, we provide the first large-scale report of *CTNNA1* sequencing findings on MGPT through a commercial lab. The data reveal multiple new *CTNNA1* LOF variants, including a new truncating variant found in multiple families that may represent a risk factor for early-onset diffuse gastric cancer. These data also provide an important overview of the demographics and cancer history of *CTNNA1* LOF variant carriers, which may aid in clinical decision making.

MATERIALS AND METHODS {#Sec2}
=====================

Patient cohort {#Sec3}
--------------

Personal and family history information from submitted requisition forms and medical records (when available) were reviewed for 151,425 individuals who underwent germline genetic testing between October 2015 and July 2019. All patient data was de-identified before analysis under Western Institutional Review Board (IRB) protocol number 1167406, which allowed for study and publication of de-identified patient data. Ethnicity was provided by all patients at the time of test ordering and was grouped for analysis based on categories used in population databases.

Genetic testing {#Sec4}
---------------

Genes analyzed for each patient were chosen at the discretion of the ordering clinician. All MGPT included *CTNNA1* and *CDH1*. Sample types for this cohort included blood and saliva. Once extracted, DNA was processed and subjected to paired-end sequencing on an Illumina next-generation sequencing platform (depth of coverage 50× minimum, 350× average), as described previously.^[@CR13]^ Variants were subjected to clinical interpretation using refined American College of Medical Genetics and Genomics criteria (Sherloc).^[@CR14]^ All *CTNNA1* variants included on clinical genetic testing reports provided to ordering providers were classified as variants of uncertain significance (VUS). *CTNNA1* VUSs included *CTNNA1* LOF variants, which were defined as variants predicted to lead to protein truncation (nonsense and frameshift variants), large deletions of one or more exons, or consensus splice site variants predicted to disrupt splicing in *CTNNA1*, as well as *CTNNA1* missense VUSs, which were defined as missense variants detected in *CTNNA1* that were not classified as benign or likely benign. De-identified variants and their interpretations from this study have been submitted to ClinVar (National Center for Biotechnology Information, Bethesda, MD; <http://www.ncbi.nlm.nih.gov/clinvar>).

*CTNNA1* c.1351C\>T families {#Sec5}
----------------------------

Probands with the *CTNNA1* c.1351C\>T variant (p.Arg451\*, reference transcript NM_001903.3) were separately consented for enrollment into IRB-approved research protocols at the University of Pennsylvania Perelman School of Medicine (Philadelphia, PA) or City of Hope (Duarte, CA). Once consent was obtained, detailed personal and family history was obtained to allow for pedigree generation. Tissue sections from individuals with gastric adenocarcinoma were acquired, and immunohistochemistry (IHC) of these formalin-fixed paraffin-embedded tissues was performed using an antibody against human α-E-catenin (Thermo Fisher 13--9700, clone alpha-CAT-7A4) using a heat-induced epitope retrieval method. Heat-induced epitope retrieval was performed for 20 minutes with ER2 solution (Leica Microsystems AR9961). Incubation with the α-E-catenin antibody at 1:100 was performed for 15 minutes followed by an 8-minute postprimary step and an 8-minute incubation with polymer HRP. Blocking with endogenous peroxidase for 5 minutes was performed followed by 10 minutes with DAB. Slides were washed three times between each step with bond wash buffer or water. IHC staining was captured on a Leica Bond-IIITM instrument using the Bond Polymer Refine Detection System (Leica Microsystems DS9800).

Statistical analysis {#Sec6}
--------------------

Fisher's exact test was utilized to calculate *p* values for the difference between the frequency of breast and gastric cancers in individuals with *CTNNA1* LOF variants compared with all individuals tested in the cohort. Significance is defined as *p* \< 0.05.

RESULTS {#Sec7}
=======

Over the study period, *CTNNA1* sequencing was performed in 151,425 individuals (Fig. [1](#Fig1){ref-type="fig"}). Of these 151,425 individuals, 1240 (0.8%) had a personal history of gastric cancer, and 52,093 (34%) had a personal history of breast cancer. 51,185 (34%) had a history of a nongastric, nonbreast cancer, and 46,907 (31%) had no personal history of cancer.Fig. 1Individuals undergoing *CTNNA1* sequencing.Flow chart showing prior cancer history of all individuals undergoing *CTNNA1* sequencing between October 2015 and July 2019, as well as delineation of the *CTNNA1* sequencing results. *LOF* loss of function, *VUS* variant of uncertain significance.

Of the individuals who underwent *CTNNA1* sequencing, 52 individuals (0.03% of those tested) had *CTNNA1* LOF variants detected. Detailed history was available on 33 individuals with *CTNNA1* LOF variants (Table [1](#Tab1){ref-type="table"}), including 2 males (6%) and 31 females (94%). The 33 individuals with detailed history available were from 29 different families, with 4 of these individuals being identified via cascade testing in 2 of the families. Among the 29 different families there were a total of 21 unique *CTNNA1* LOF variants, with only *CTNNA1* c.2023C\>T (p.Gln675\*) being previously reported in the literature.^[@CR8]^ Of those with LOF variants, all affected probands had negative *CDH1* testing, and no individuals had another pathogenic/likely pathogenic variant identified in any high or moderate risk cancer susceptibility gene. Four (12%) individuals had a personal history of diffuse gastric cancer, which was significantly greater than the 0.8% (1240/151,425) of the tested cohort with gastric cancer (*p* = 0.0002). Twenty-two (67%) individuals had a personal history of invasive breast cancer or ductal carcinoma in situ, excluding 1 individual with known lobular carcinoma in situ (LCIS), which was significantly greater than the 34% (52,093/151,425) of the tested cohort with breast cancer (*p* = 0.0002). Of the 7 (21%) individuals who were unaffected with cancer, the majority (5 individuals) had a family history of gastric and/or breast cancer in a first-degree relative.Table 1*CTNNA1* loss-of-function (LOF) variants identified.Family IDAncestryGenderHistory of gastric cancerHistory of breast cancerFDR with gastric or breast cancerHGVSProtein effect1Black/African AmericanF--PNS 40s and 50sBreast 70sDeletion of entire coding sequenceDeletion2White/Caucasian, Native AmericanF--Ductal 70sGastric 20s; Breast 30s and 40s**c.105+1G\>CSplice site**3White/Caucasian, Ashkenazi JewishF--PNS 70s--**c.105+1G\>CSplice site**4White/CaucasianF--Lobular 60s--**c.105+1G\>CSplice site**5White/CaucasianF--PNS 50s--**c.105+1G\>CSplice site**6White/CaucasianF--PNS 60sc.392dupTp.Leu131Phefs\*137White/CaucasianF--PNS 60sBreast 30s and 40sc.468+1G\>ASplice site8White/CaucasianFDiffuse 30s--Ductal 50s**c.926_936delp.Leu309Hisfs\*2**MediterraneanF--Ductal 50sDiffuse 30s**c.926_936delp.Leu309Hisfs\*2**White/Caucasian, ItalianF----Diffuse 30s; Ductal 50s**c.926_936delp.Leu309Hisfs\*2**9White/CaucasianF--PNS 30s--c.1078_1081delp.Arg360Valfs\*810UnknownF--PNS unknown ageBreast 30s, unknown age, and unknown agec.1246_1294delp.Val416Argfs\*1411White/CaucasianF--PNS 70sBreast 40sc.1261C\>Tp.Gln421\*12White/CaucasianF--PNS 30s--c.1330dupp.Glu444Glyfs\*2313White/Caucasian, HispanicFDiffuse 20s----**c.1351C\>Tp.Arg451\***White/CaucasianF----Diffuse 20s**c.1351C\>Tp.Arg451\***White/Caucasian, HispanicM----Diffuse 20s**c.1351C\>Tp.Arg451\***14HispanicFDiffuse 30s--Gastric 50s**c.1351C\>Tp.Arg451\***15White/CaucasianF--Ductal 50s--**c.1351C\>Tp.Arg451\***16White/CaucasianF--Ductal 40s--c.1390-?\_1546+?delDeletion Exon 1117Black/African AmericanF--PNS 30s--c.1613_1617 dupTGGACp.Arg540Trpfs\*1818Black/African AmericanFDiffuse 10s----c.1997delGp.Gly666Alafs\*5619Ashkenazi JewishF----Breast 70s**c.2023C\>T**^a^**p.Gln675\***^a^20HispanicF--PNS 70sGastric 60s, 70s, and 70s; Breast 60s**c.2023C\>T**^a^**p.Gln675\***^a^21White/Caucasian, Ashkenazi JewishM------**c.2023C\>T**^a^**p.Gln675\***^a^22White/CaucasianF----Breast 40s and 40sc.2191C\>Tp.Arg731\*23White/CaucasianF--PNS 60sBreast 40s, 40s, 50s, 50s, and 80sc.2393_2394insTp.Glu799Argfs\*7924White/CaucasianF--PNS 50s and 70s--c.2443_2462dupp.Ala822Profs\*425White/CaucasianF--PNS 60sBreast 30s and 40sc.2491C\>Tp.Gln831\*26White/Caucasian, Ashkenazi JewishF--Ductal 40s--c.2621_2622delAAp.Lys874Thrfs\*327White/CaucasianF--Ductal 50s--c.2621_2627 dupAACAGGAp.Asp876Glufs\*428Ashkenazi JewishF------**c.2635_2636delCAp.Gln879Aspfs\*4**29White/CaucasianF--PNS ≤40s--**c.2635_2636delCAp.Gln879Aspfs\*4***FDR* first degree-relative, *HGVS* Human Genome Variation Society, *PNS* pathology not specified, bolded variants were identified in more than one individual.^a^Previously reported *CTNNA1* variant.^[@CR7]^

Taking together the probands and first-degree relatives in the 29 families, 6 (21%) families had a history of gastric cancer, 3 (10%) families had a history of gastric and breast cancer, 21 (72%) families had a history of breast cancer without gastric cancer, and 2 (7%) families had no reported history of gastric or breast cancer. In addition to these LOF variants, 1057 individuals (0.7% of those tested) had a *CTNNA1* missense VUS identified, representing 302 distinct variants (Supplemental Table [1](#MOESM1){ref-type="media"}).

Of particular interest from the LOF variants was the novel *CTNNA1* c.1351C\>T nonsense variant, which is predicted to lead to a protein truncation product (p.Arg451\*). This *CTNNA1* variant was identified in three separate families. The proband of family 13 is a Caucasian female who was diagnosed with metastatic, poorly differentiated, diffuse signet-ring cell gastric adenocarcinoma at age 25 (Fig. [2a](#Fig2){ref-type="fig"}). Immunohistochemistry (IHC) revealed loss of α-E-catenin expression in the gastric adenocarcinoma with retained α-E-catenin expression in the normal gastric epithelium (Fig. [2b, c](#Fig2){ref-type="fig"}). The patient's mother, who had thyroid cancer at age 47 and LCIS at age 53, as well as her unaffected brother, both tested positive for the *CTNNA1* variant and underwent upper endoscopy with Cambridge protocol biopsies and no gross lesions were identified and no foci of signet-ring cells were identified on biopsies. The remainder of the family history is significant for her maternal grandfather with prostate cancer at age 65 and colorectal cancer at age 70, and a maternal first cousin once removed with breast cancer diagnosed at age 50.Fig. 2*CTNNA1* family 13.**a** Pedigree of family 13. Red = gastric cancer, yellow = breast cancer and lobular carcinoma in situ (LCIS), gray = other cancers. (**b**, **c**) Hematoxylin & eosin (H&E) staining and α-E-catenin immunohistochemistry (IHC) of endoscopic biopsies of the family 13 proband's diffuse signet-ring cell gastric adenocarcinoma (**b**) and the proband's unaffected normal gastric mucosa (**c**). Images obtained at 20×.

The proband of family 14 is a Hispanic female who had metastatic, poorly differentiated, diffuse signet-ring cell gastric cancer diagnosed at age 39 (Fig. [3a](#Fig3){ref-type="fig"}). IHC of a lymph node metastasis for α-E-catenin demonstrated decreased expression of α-E-catenin in the tumor compared with adjacent lymphoid tissue (Fig. [3b](#Fig3){ref-type="fig"}). The proband's mother was diagnosed with gastric cancer at age 50 and died at age 51, and her maternal cousin was diagnosed with head and neck cancer at age 28. To our knowledge, no other members of family 14 have undergone *CTNNA1* testing.Fig. 3*CTNNA1* family 14.**a** Pedigree of family 14. Red = gastric cancer, gray = other cancers. **b** Hematoxylin & eosin (H&E) staining and α-E-catenin immunohistochemistry (IHC) of a lymph node metastasis of the family 14 proband's diffuse signet-ring cell gastric adenocarcinoma. Images obtained at 20×.

Finally, the proband of family 15 is a Caucasian female with grade 1, ER+/PR+/Her2- invasive ductal breast cancer diagnosed at age 53 (Fig. [4](#Fig4){ref-type="fig"}). This proband also had a history of a basal cell carcinoma at age 43. The family history is significant for her mother with pancreatic cancer diagnosed at age 94, a paternal cousin with brain cancer at age 35, and another paternal cousin with thyroid cancer at age 40. No other members of her family have undergone *CTNNA1* testing.Fig. 4*CTNNA1* family 15.Pedigree of family 15. Yellow = breast cancer, gray = other cancers.

DISCUSSION {#Sec8}
==========

MGPT includes analysis of well characterized, highly penetrant cancer risk genes, which are important for proper risk stratification for affected individuals and their families. However, the expansion of the number of genes available on MGPT has allowed for more widespread testing of "preliminary evidence genes" such as *CTNNA1*, which has been considered a potential diffuse gastric cancer susceptibility gene similar to *CDH1*. Testing for preliminary evidence genes has become increasingly important for better characterization of the associated clinical phenotypes. We report the results of germline *CTNNA1* testing in a large cohort of individuals undergoing genetic testing at a commercial lab. We demonstrate that *CTNNA1* LOF variants are detected at low rates in this large cohort, and that *CTNNA1* LOF variants are found in individuals with personal and/or family histories of gastric and/or breast cancer.

In our cohort undergoing genetic testing, *CTNNA1* LOF variants were found at a rate of 1 in 2912 individuals. This is a more frequent rate than that observed in the Genome Aggregation Database (gnomAD), where *CTNNA1* LOF variants were observed in 1 in 17,682 individuals (8 *CTNNA1* LOF variants of 141,456 individuals) (unpublished, Karczewski KJ, Francioli LC, Tiao G, et al. Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes, bioRxiv, 2019:531210). This higher rate of *CTNNA1* LOF variants in our cohort suggests there may be enrichment in *CTNNA1* LOF variants in a cohort ascertained for personal/family history of cancer when compared with the general population. However, *CTNNA1* LOF variants were found less frequently than pathogenic/likely pathogenic *CDH1* variants in the testing cohort, which were present in 106 of 151,425 individuals tested, for a rate of 1 in 1429 individuals.

*CTNNA1* LOF variants were found previously in families meeting criteria for HDGC syndrome with a highly penetrant gastric cancer phenotype.^[@CR7]--[@CR11]^ However, two other reports of *CTNNA1* LOF variants found no gastric cancer, including one individual identified with a *CTNNA1* c.1183delC (p.Leu395Trpfs\*10) variant in a large study of MGPT on unselected Chinese breast cancer patients,^[@CR15]^ and a *CTNNA1* c.2101G\>T (p.Glu701\*) variant identified in a study examining truncating protein variants in neurodevelopmental disorders.^[@CR16]^ In our cohort, 12% of the individuals found to have a *CTNNA1* LOF variant had a history of diffuse gastric cancer, while 21% of those found to have a *CTNNA1* LOF variant had either a personal or family history of gastric cancer. Although there was enrichment for gastric cancer in *CTNNA1* LOF variant carriers, the rate of gastric cancer observed in our cohort may appear surprisingly lower than expected given prior reports strongly associating *CTNNA1* with gastric cancer.^[@CR7]--[@CR11]^ However, decreased penetrance estimates are seen in *CDH1* carriers when analyzing unselected cohorts rather than highly penetrant families, thus decreasing the selection bias.^[@CR17],[@CR18]^

*CDH1* variants have also been associated with increased lobular breast cancer risk.^[@CR19],[@CR20]^ In examining personal and family history of breast cancer in *CTNNA1* LOF carriers, we found 67% of carriers had a history of breast cancer, while 83% of carriers had either a personal history of or a first-degree relative with breast cancer. This high percentage may be influenced by the population undergoing genetic testing, where over one-third of individuals tested had a personal history of breast cancer. However, despite the high number of individuals with a personal history of breast cancer in the testing cohort, there was still statistically significant enrichment for breast cancer in *CTNNA1* LOF carriers. Given the limitations in data collection, it is unknown if the majority of breast cancer seen in *CTNNA1* LOF families is predominantly ductal or lobular, which prevents determination of whether the observed breast cancer enrichment is specific for lobular and/or ductal breast cancers. However, while most individuals did not specify the breast cancer subtype, the majority of breast cancers where a subtype was reported were ductal. It is also worthwhile to note that although many *CTNNA1* LOF carriers had a personal history of breast cancer, the prevalence of LOF variants among individuals with breast cancer was low at 0.04% (22 of 52,093).

Of additional importance is whether *CTNNA1* LOF variants are directly involved in increasing gastric and/or breast cancer risk. *CTNNA1* codes for α-E-catenin, which interacts with the cell--cell adhesion molecule E-cadherin, the protein product of *CDH1*.^[@CR21]^ Prior studies demonstrated that α-E-catenin expression is lost in gastric cancers of individuals carrying *CTNNA1* LOF variants, thus inferring a potential role in gastric carcinogenesis.^[@CR7],[@CR8]^ We observed similar findings in our families with the *CTNNA1* c.1351C\>T nonsense variant, where the early-onset diffuse gastric cancers showed decreased α-E-catenin expression. This evidence points toward a potential association of *CTNNA1* LOF variants with increased gastric cancer risk, especially for certain variants such as *CTNNA1* c.1351C\>T; however, further study of the biological mechanism of this potential association is needed. The site of truncation may play a role in mediating risk. In families 23--29 the truncations are located in the C-terminus and would not be expected to lead to nonsense-mediated decay, which is of potential interest as none of these individuals nor their first-degree family members were reported to have a history of gastric cancer.

A challenge of testing preliminary evidence genes is deciding when to designate LOF variants as pathogenic/likely pathogenic given insufficient evidence for a disease-causing role.^[@CR22]^ Given the limited evidence, commercial labs may not call *CTNNA1* LOF variants pathogenic/likely pathogenic, which is standard practice when the gene--disease association is uncertain, and instead all of these variants may be categorized as VUSs. Therefore it is incumbent on the ordering clinician to closely examine any *CTNNA1* variant discovered in the context of other clinical and family history information to properly utilize these results for appropriate clinical care. It is likely that clinical guidelines for management of *CTNNA1* LOF carriers, for example from the International Gastric Cancer Linkage Consortium (IGCLC), may help enable commercial labs to call these variants pathogenic/likely pathogenic. Further complicating matters with *CTNNA1* is the rate of missense VUSs identified. Including the 1057 missense VUSs with the 52 LOF variants, 0.7% of the tested population was identified to have a *CTNNA1* VUS.

The management of individuals with *CTNNA1* LOF variants remains challenging. Currently, there are no guidelines or expert opinion panels that provide concrete clinical recommendations for *CTNNA1* LOF carriers, and therefore, management of these individuals must be individualized. For gastric cancer risk, while a risk-reducing total gastrectomy for a *CTNNA1* LOF variant was reported,^[@CR8]^ given the preliminary evidence surrounding *CTNNA1* as well as the unclear and possibly lower than expected gastric cancer risk, risk-reducing total gastrectomy will likely not be a reasonable choice for all individuals with *CTNNA1* variants at this time. However, whether or not to pursue gastric cancer surveillance, in a similar manner to *CDH1* carriers who defer gastrectomy, can be considered. While it has been reported that invasive lobular carcinoma is more common in *CDH1* carriers,^[@CR19],[@CR20]^ we do not know if this will also pertain to *CTNNA1*, as the majority of our cohort who reported a personal history of breast cancer did not specify pathology. Breast cancer management of these individuals will also need to be addressed as more data are generated; however, due to limited evidence, we do not suggest altering breast cancer surveillance in *CTNNA1* carriers at this time, and therefore the recommendation for breast cancer screening should be individualized based on personal and family history of the disease, not the presence or absence of *CTNNA1* LOF variants.

Given the uncertainties in management, it is important that individuals who undergo genetic testing for preliminary evidence genes, such as *CTNNA1*, have thorough pretest genetic counseling. Furthermore, *CTNNA1* LOF carriers should be strongly encouraged to enroll in research registries to allow accurate collection of personal and family history, as well as collection of longitudinal outcomes, since these data will be critical for refining the cancer risk spectrum of *CTNNA1*.

There are several limitations in our study. First, other than the three *CTNNA1* c.1351C\>T families, personal and family history data were obtained from genetic testing requisition forms, and unable to be confirmed by direct review of the medical records. However, recent data have demonstrated that ordering clinicians typically do an accurate job of reporting personal and family history on requisition forms.^[@CR23]^ Another limitation to our study is that the breast cancer type was provided in less than half of the reported breast cancers in the *CTNNA1* LOF carriers. Additionally, individuals undergoing *CTNNA1* requisitioning are subject to selection bias as these individuals primarily had a personal or family history of cancer. Therefore, it is possible that if *CTNNA1* testing was performed in a completely unselected population, there may be a lower number of gastric and/or breast cancers in *CTNNA1* families than we have reported. Finally, given the small number of *CTNNA1* LOF variant carriers as well as the limited complete family history for the majority of these carriers, calculation of accurate cancer risk estimates was not feasible.

This study provides the first large-scale report of *CTNNA1* LOF variants in individuals undergoing genetic testing for cancer risk assessment. We demonstrate that *CTNNA1* LOF variants are detected on MGPT with a majority of the individuals with a LOF variant having breast cancer and a minority having gastric cancer. These data show that the gastric cancer risk associated with a *CTNNA1* LOF variant may be lower than initially predicted; however, there may be specific variants, such as the *CTNNA1* nonsense variant c.1351C\>T, which may be a significant risk factor for early-onset diffuse gastric cancer. Management of individuals with *CTNNA1* LOF variants remains challenging, and capturing affected individuals in prospective registries will be critical to better determine the true cancer risks associated with *CTNNA1* LOF variants.
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